Guardant Health, Inc.
GHHealthcareNASDAQDiagnostics & Research · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 28
Headquartered within the healthcare sector, Guardant Health, Inc. focuses on Diagnostics & Research services and products. Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company carries a $17.66B market cap, placing it firmly in the large-cap category. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Market Cap
$17.66B
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-231.95
EPS (TTM)
$-3.39
EPS (Fwd)
$-0.57
ROE
—
ROA
-17.2%
Cash
$1.10B
Total Debt
$1.70B
Free CF
-$85.4M
52W Change
228.0%
Annual Financials
Cash vs Debt
Guardant Health, Inc. carries $1.70B in total debt against $1.10B in cash reserves — debt is roughly 1.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$85.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $449.5M (2022) to $982.0M (2025), reflecting a 118% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GH.